Year None2022202120202019201820172016 May 16, 2022 A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease Source Blood Apr 14, 2022 Mitapivat versus Placebo for Pyruvate Kinase Deficiency Source New England Journal of Medicine For details on our former oncology programs, visit https://www.servier.us/.
May 16, 2022 A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease Source Blood
Apr 14, 2022 Mitapivat versus Placebo for Pyruvate Kinase Deficiency Source New England Journal of Medicine